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Mutations in theRP2gene lead to asevere formofX-linked retinitis pigmentosa.RP2patients frequently present
with nonsensemutations and no treatments are currently available to restore RP2 function. In this study, we re-
programmed fibroblasts from anRP2 patient carrying the nonsensemutation c.519C>T (p.R120X) into induced
pluripotent stemcells (iPSC), anddifferentiated thesecells into retinal pigmentepithelial cells (RPE) tostudy the
mechanisms of disease and test potential therapies. RP2 protein was undetectable in the RP2 R120X patient
cells, suggesting a disease mechanism caused by complete lack of RP2 protein. The RP2 patient fibroblasts
and iPSC-derived RPE cells showed phenotypic defects in IFT20 localization, Golgi cohesion and Gb1 traffick-
ing. These phenotypes were corrected by over-expressing GFP-tagged RP2. Using the translational read-
through inducing drugs (TRIDs) G418 andPTC124 (Ataluren), wewere able to restore up to 20%of endogenous,
full-lengthRP2protein inR120Xcells. This level of restoredRP2wassufficient to reverse thecellular phenotypic
defects observed in both the R120X patient fibroblasts and iPSC-RPE cells. This is the first proof-of-concept
study to demonstrate successful read-through and restoration of RP2 function for the R120X nonsense muta-
tion. The ability of the restored RP2 protein level to reverse the observed cellular phenotypes in cells lacking
RP2 indicates that translational read-through could be clinically beneficial for patients.
INTRODUCTION
Retinitispigmentosa (RP)definesaclinicallyandgeneticallydiverse
groupofinheritedretinaldystrophies,whicharecharacterizedbypro-
gressive loss of visual functiondue to photoreceptor cell dysfunction
anddegeneration.TheX-linkedformsofRP(XLRP)areparticularly
severe, typically presenting in affected males in the first or second
decade, with a rapid course of vision loss (1). Mutations in the
XLRP gene RP2 account for 15% of XLRP cases (2–9). Some
RP2 patients have an early macular involvement, with early-onset
macular atrophy and poor visual acuity in childhood (10,11).
The RP2 protein is ubiquitously expressed in human tissues
and does not appear to be enriched in retina (12). However,
patients with RP2 mutations only have a retinal dysfunction,
without any other apparent organ involvement, so an important
question is why loss of RP2 leads specifically to RP. It is also
unclear whether mutations in the ubiquitously expressed RP2
protein concomitantly affect photoreceptor and retinal pigment
epithelium (RPE) cell function, or if one precedes the other, as
it is expressed in both cell types (13,14). Interestingly, the clin-
ical presentation of some RP2 patients can resemble choroider-
emia (11), which is caused by the lack of Rab escort protein
(REP1) and affects both the RPE and photoreceptors (15).
Like REP1, RP2 has been implicated in vesicle traffic,
potentially in cilia-associated traffic. A pool of RP2 is localized
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at the ciliary apparatus, basal body and cilium-associated centri-
ole of photoreceptor cells (16–18) and RP2 also localizes to the
Golgi, periciliary ridge andplasmamembrane, implying a role for
RP2 in primary cilia protein trafficking (16,17,19,20). RP2 acts as
a GTPase activating protein (GAP) for the small GTPase Arl3
(21), which is essential for cilia function (13,22,23), further
supporting the involvement of RP2 in cilia function.
The development of human induced pluripotent stem cell
(iPSC) technology has greatly enhanced the potential for under-
standing disease mechanisms through the generation of specific
cell types affected by a particular disease directly from patient
cells. RPE cells are essential for visual function, with an import-
ant role in many processes; for example, the visual cycle and
phagocytosis of outer segments (24–26). The dysfunction or
death of RPE cells can cause a range of human retinal degenera-
tive diseases, including retinitis pigmentosa. Therefore, human
iPSCs differentiated into RPE cells present an opportunity to
study retinal disease aetiology (27–30). The ability to derive
specific cell types also facilitates the testing of promising
drugs in vitro within the cellular and mutational context of the
disease. This is particularly important for potential therapies
that are sequence or mutation specific and would otherwise
require the development of humanized, knock-in animalmodels.
No treatments are currently available to restore RP2 function
in patients. RP2 patients frequently present with nonsensemuta-
tions (nine reported), and of these Arg120stop (R120X) is the
most common, potentially as a mutation hotspot (3,31–35).
Therapies that aim to restore translational read-through (TR)
could therefore benefit a large group of RP2 patients. Nonsense
mutations lead to premature termination codons (PTCs) that
promote mRNA degradation through nonsense-mediated
decay (NMD). NMD is a quality control pathway that targets
transcripts inwhich translation is arrested, degrading potentially
harmful mRNAs that have the potential to produce truncated
polypeptides (36,37). Several compounds can suppress PTCs
by inhibiting translationally active ribosomes, thereby hamper-
ing their proof-reading function, compromising the integrity of
codon–anticodon pairing, which leads to the insertion of a
near cognate tRNA codon at the stop codon (38). This results
in the incorporation of an amino acid at the site of the mutation
induced stop codon, and therefore, potentially, expression of a
full-length protein (39,40). Aminoglycoside antibiotics, such
as gentamicin (G418), have been shown to cause translational
read-through of PTCs and restore full-length protein expression
inavarietyof contexts (41–44).Anotherpromising translational
read-through inducing drug (TRID) is the compound PTC124
or Ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-
benzoic acid). PTC124 was effective in restoring PTC read-
through in several in vitro and in vivo studies for different
diseases, including Duchenne muscular dystrophy and Usher
syndrome (41,45–49). However, the feasibility of TRIDs
needs to be evaluated for each respective disease and mutation,
as the therapeutic outcome is influenced by the type of PTC, the
genomic context of the nonsense mutation and the pathophysi-
ology of the disorder.
Previously, we investigated the ability of aminoglycoside
antibiotics to stimulate TR in RP2 R120X patient lymphoblast
cells, but these drugs did not restore detectable levels of full-
length RP2 protein (50). Recent advances in TRID technology,
coupled to the ability to reprogramme patient cells into retinal
cells, such as RPE that might be affected by the loss of RP2,
and a greater understanding of RP2 function argue that it is
timely to revisit the potential of TRIDs for RP2 stop mutations.
Here, we characterized the phenotype of RP2 patient fibroblast
and iPSC-derived RPE cells and tested for potential read-
through of the R120Xmutation and restoration of RP2 function.
RESULTS
Patient R120X fibroblasts are RP2-null cells with
cilia-associated trafficking defects
Patient R120X fibroblasts were derived from a skin biopsy of a
24-year-old male. The nonsense mutation c.519C.T (p.R120X)
was confirmed in the fibroblasts by direct sequencing (Supple-
mentary Material, Fig. S1A). Fibroblast identity was confirmed
by immunocytochemistry (ICC) using a fibroblast specific
surface protein antibody (Supplementary Material, Fig. S1B).
RP2 R120X patient fibroblasts and male control fibroblasts
were analyzed for RP2 expression by ICC and western blotting.
No RP2 staining was detectable by ICC in R120X fibroblasts
compared with controls, which showed RP2 at the plasmamem-
brane andbasal body as previously described (16) (Fig. 1A). Fur-
thermore, no full-length or truncatedRP2protein expressionwas
detectable by western blotting (Fig. 1B). The RP2 antibody
(S974) used in this study has been extensively characterized
(12) and shown to detect RP2 protein fragments containing
just the first 15 amino acids of RP2 (51). Knock-down of RP2
in ARPE19 cells by siRNA does not affect cilia incidence or
cilia length (16). Similarly, no differences in cilia incidence or
length were detected in R120X fibroblasts compared with con-
trols (Supplementary Material, Fig. S1C–F). Earlier reports
have suggested that knock-down of RP2 results in accumulation
of theRP2 interacting proteinPolycystin 2 (PC2) at the ciliary tip
(17), and reduces the ciliary localization of Nephronophthisis 3
(NPHP3) (20). Therefore, we investigated whether localization
of these proteins is affected in R120X fibroblasts. Staining for
endogenous PC2 or NPHP3 revealed no qualitative or quantita-
tive differences in staining pattern between ciliated R120X and
controlfibroblasts (SupplementaryMaterial, Fig. S1G–J).Other
reports showed that RP2 siRNAknock-down resulted in reduced
Golgi cohesion and transducin subunit Gb1 membrane associ-
ation, as well as increased IFT20 dispersal from the basal body
(16,52). Importantly, the R120X patient cells also showed mis-
localization of IFT20 and Gb1 and a disrupted Golgi morph-
ology, as determined by quantitation of their area by unbiased
ImageJ measurement of threshold staining (Fig. 1C–I). To de-
termine whether these phenotypic defects were specific to the
loss of RP2 function in the R120X patient fibroblasts, we per-
formed a rescue experiment in which control and R120X fibro-
blasts were transfected with either RP2-GFP or empty GFP
plasmid with subsequent staining for either IFT20 or the Golgi
marker GM130. The localization of IFT20 at the basal body
and Golgi morphology was rescued by overexpression of
RP2-GFP in R120X fibroblasts, as assessed by a decrease in
area compared with control levels (Fig. 1C–F). To investigate
Gb1 traffic, R120X patient cells were cotransfected with
FLAG-Gb1 with either RP2-GFP or empty GFP. In the
absence of RP2, Gb1 overexpression resulted in a mainly punc-
tate, cytoplasmic staining pattern, as reported previously (52)
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(Fig. 1G); however,whenGb1wasco-expressedwithRP2-GFP,
Gb1 stainingwasobservedat theplasmamembrane and the level
of co-localization with the plasma membrane marker pan-
cadherin was increased, when measured by Pearson’s correl-
ation and the Mander’s co-localization coefficient (Fig. 1G–I).
These data confirm that these cellular phenotypes are a
Figure1.CharacterizationofRP2R120Xfibroblast cells. (A)RP2 (red) localizes to theplasmamembraneand thebasal body (pericentrin, green) in controlfibroblasts,
whileR120Xfibroblastswere negative for expression ofRP2by ICC.The inset shows a highermagnification of the basal body region boxed in themerge image. Scale
bar 5 mm. (B)Western blot showing no RP2 protein was detected in R120X fibroblasts compared with control fibroblasts. GAPDHwas used as a loading control (C)
R120X or control cells were transfected by electroporation with empty GFP plasmid or RP2-GFP. R120X fibroblasts show dispersed IFT20 staining (red) compared
with control cellswhen transfectedwithGFPalone. This phenotypewas rescuedbyoverexpressionofRP2-GFP inR120Xcells. Scale bar 10 mm. (D) IFT20dispersal
from the basal bodywas quantified bymeasuring the area of IFT20 per cell using a Threshold Plugin in ImageJ. (E) Cellswere transfected as described above. Control
and R120X fibroblasts were stained with an antibody for the cisGolgi component GM130 (red) to determine whether the loss of RP2 affects Golgi cohesion. GM130
showsadispersed localization pattern inR120Xfibroblasts comparedwith controls.This phenotypewas rescuedbyoverexpressionofRP2-GFP.Scale bar 10 mm. (F)
Golgi dispersal was analyzed as described above. (G) R120X or control fibroblast cells were transfected with FLAG-Gb1 (red), GFP alone or RP2-GFP and
FLAG-Gb1. In R120X cells transfected with FLAG-Gb1 and RP2-GFP, FLAG-Gb1 localized to the plasma membrane, comparable to control cells. Scale bar
10 mm. (H and I) FLAG-Gb1 plasma membrane staining was quantified by calculating the Pearson’s and Mander’s co-localization efficient in cells co-stained for
FLAG and the plasmamembranemarker cadherin, using the JaCOP plug-in and ImageJ software. ∗P ≤ 0.05, values aremean+2 SEM,N ¼ 3 biological replicates.
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consequence of the lack of RP2 function in R120X patient-
derived cells.
Reprogramming RP2 R120X fibroblasts into iPSCs
and differentiation into RPE cells
To investigate the potential consequences of the loss of function-
al RP2 on retinal cells we reprogrammed patient fibroblasts into
iPSCs and subsequently differentiated these into ciliated RPE
cells (Fig. 2A). Briefly, R120X fibroblasts and control male
fibroblasts were reprogrammed by electroporation with episo-
mal plasmids containing Oct4, Sox2, Klf4, Myc and Lin28
(Fig. 2A). iPSC colonies were isolated and expanded. The plur-
ipotency of the isolated iPSC lines was confirmed using iPSC-
specific antibodies (Fig. 2B). RT-PCR confirmed induction of
endogenous reprogramming genes and loss of episomal tran-
scripts (Supplementary Material, Fig. S2).
Two clonal iPSC lines were differentiated into RPE cells by
culturing the iPSC in HESC-bFGF medium. After 6 weeks,
pigmented RPE colonies formed and were purified by manual
excisionusing crescent blades and cultured until fully pigmented
before further analysis (Fig. 2A).The isolatedpatient andcontrol
RPE cells displayed classic RPE cobblestone morphology and
were pigmented (Fig. 2C). In addition, RPE cell morphology
was confirmed using cell differentiation and RPE specific
markers, such as Bestrophin, MerTK, the tight junction marker
ZO-1, the melanosome marker Pmel17 (Fig. 2D) and the
retinal isomerase RPE65 (Fig. 2E). No qualitative differences
could be observed between the control and RP2 iPSC-derived
RPE using these RPE markers. In addition, cilia incidence and
morphology was comparable in both R120X and control RPE
lines (Supplementary Material, Fig. S3A). In contrast, the
R120X RPE cells had no detectable RP2 protein (Fig. 2G) and
RP2 was absent from the basal body and the plasma membrane
in these cells, compared with controls (Fig. 2F).
IFT20 localization and Golgi cohesion were compared in two
independent iPSC-derivedR120XRPE lines (Line 1 andLine 2)
and two iPSC-derivedRPEmale controls (BJ andLPP).The area
of pericentriolar IFT20 staining was increased in both R120X
lines, with no significant difference between the two controls
(Supplementary Material, Fig. S3B). Similarly, the area of
three different Golgi markers (GM130, Giantin and TGN) was
increased compared with controls in both R120X lines,
showing disrupted Golgi cohesion (Supplementary Material,
Fig. S3C–E). Staining for endogenous Gb1 in control and
R120XRPEcells showed thatGb1 localized to theplasmamem-
brane in controlRPEcells, but had adiffuse cytoplasmic staining
pattern in R120X RPE cells (Fig. 2H). These data also confirm
that the R120X fibroblasts and RPE display similar cellular phe-
notypes that are specific and consistent.
G418 and PTC124 can restore RP2 protein in patient R120X
fibroblasts
Since no RP2 protein was detectable in the R120X cells by
western blotting (Figs 1B and 2E), we reasoned that TRIDs,
such as G418 and PTC124, could potentially restore some RP2
expression. Reverse transcriptase-quantitative PCR (RT-qPCR)
showed that RP2 mRNA levels in R120X fibroblasts were
80% lower than levels in male control cells, suggesting that
the mutant RP2 R120X transcript is subjected to NMD
(Fig. 3A and B). A dose response over 24 h revealed that the
most effective dose of 750 or 500 mM G418 resulted in an
40% increase in R120X RP2 mRNA levels (Fig. 3A and B).
In contrast, the most effective dose of PTC124 treatment
(10 mg/ml) appeared to increase RP2 mRNA levels compared
with untreatedR120Xcells; however, this did not reach statistic-
al significance (Fig. 3A and B). These data, at the most effective
doses tested for the compounds, suggest a difference in potency
or different mechanism of action for the TRIDs G418 and
PTC124. Next, we analyzed RP2 protein expression in R120X
fibroblast cells by western blotting following 24-hour treatment
with G418 or PTC124. The amount of restored full-length RP2
protein was quantified using a calibration curve derived from
purified recombinant HIS-tagged RP2 (Supplementary Mater-
ial, Fig. S4A). Treatment with G418 (750 mM dose) or
PTC124 (10 mg/ml dose) led to an increase in RP2 protein to
20%and13%of control cell levels, respectively (Fig. 3C andD).
TRID mediated correction of the RP2-null cellular
phenotype
In order to determine if the increased RP2 transcript and protein
levels following treatment with G418 and PTC124 resulted in a
rescue of functional RP2, and were sufficient to reverse the
phenotypic effects, we investigated the cellular phenotype in
TRID treated R120X fibroblasts compared with untreated
cells. Initially, to test if G418 or PTC124 had any off target
effects on these phenotypes, we treated control fibroblasts with
a single 24 h dose of either 750 mM G418 or 10 mg/ml
PTC124, and IFT20 localization at the basal body and Golgi co-
hesion were examined. Neither of the TRID treatments had any
effect on these cellular markers in control male fibroblast cells
(Supplementary Material, Fig. S4B–E). As before, untreated
R120X fibroblasts showed a significantly larger IFT20 pericen-
triolar area, compared with controls (Fig. 4A). Following TRID
treatment the average area of IFT20 in each R120X fibroblast
cell was significantly reduced and comparable to control fibro-
blasts (Fig. 4A and B). Similarly, Golgi area, assessed by three
Golgimarkers,was reduced following treatment ofR120Xfibro-
blasts with either G418 or PTC124 (Fig. 4C–H).
To investigate the effect of TRID mediated RP2 rescue on
Gb1 trafficking, R120X fibroblasts were transfected with
FLAG-Gb1 and treated with a single 24 h dose of G418
(750 mM) or PTC124 (10 mg/ml). Cells were then stained for
FLAG and pan-cadherin, which was used as an independent
plasma membrane marker (Fig. 5A). Untagged RP2 and
HA-Gg1 were used as positive controls, since expression of
Gb1 with HA-Gg1 results in the translocation of Gb1 from the
cytosol to the plasma membrane, irrespective of whether RP2
is present (52). Transfection of R120X fibroblasts with
FLAG-Gb1 alone showed mainly cytosolic Gb1 staining,
whereas FLAG-Gb1 localized to the plasma membrane in
control cells and co-localized with pan-cadherin, as measured
with Pearson’s and Mander’s coefficients, in the presence
HA-Gg1 orRP2 (Fig. 5A). Treatment of FLAG-Gb1 transfected
R120X fibroblasts with G418 or PTC124 also restored plasma
membrane association of FLAG-Gb1 in R120X cells
(Fig. 5A). Co-localization of FLAG-Gb1 and cadherin was
quantified and confirmed that treatment with either G418 or
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Figure2.Generation of inducedpluripotent stemcells (iPSCs) and retinal pigment epitheliumcells (RPE) fromRP2R120Xfibroblasts. (A) Schematic representation
of iPSC and RPE cell generation from fibroblasts. A skin biopsy was taken and cut into small pieces using scalpel blades. The cells were then cultured in DMEMand
outgrowing fibroblasts from the skin biopsy were isolated manually. To reprogram fibroblasts into iPSCs, cells were electroporated with plasmids containing Oct4,
Sox2, Myc, Lin28 and Klf4, plated onto matrigel-coated dishes and cultured in mTESRmedium. Forming iPSC colonies were isolated manually. iPSC were differ-
entiated into RPE cells by culturing in HESC—bFGF medium. Pigmented RPE colonies were excised manually using crescent blades. (B) iPSC derived RPE from
controls and the RP2 R120X patient showed nuclear (DAPI, blue) localization of the iPSCmarkers Nanog (red) and Oct4 (red). Scale bar 10 mm. (C) Differentiated
control and R120X iPSC-derived RPE cells display the classic cobblestone pigmentedmorphology. Scale bar 10 mm. (D) Sectioned RPE cells were stained for RPE
and differentiationmarkers: ATP1B1 (green), Col4 (red), Bestrophin (green),MerTK (red), Pmel17 (green), ZO1 (red), mitf (green) or (E) RPE65 (green). Scale bar
10 mm (F) RP2 protein is undetectable in iPSC-derived R120X RPE cells at the plasma membrane and the basal body by ICC. Scale bar 10 mm. (G) RP2 protein is
undetectable in the iPSC-derived R120XRPE cells bywestern blotting. GAPDHwas used as a loading control. (H) SectionedRPE cells were stained for endogenous
Gb1 (green) the membrane marker wheat-germ agglutinin (WGA, red) and DAPI (blue). Gb1 localizes to the plasma membrane in control RPE cells, but shows a
diffuse cytoplasmic staining pattern in R120X RPE cells. Scale bar 10 mm.
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PTC124 restored FLAG-Gb1 plasma membrane localization in
R120Xcells to levels similar to those in control cells (Fig. 5Band
C). These findings further confirm that the mislocalization of
Gb1 in R120X fibroblasts is due to lack of RP2 and that overex-
pression of RP2 or HA-Gg1 can enhance the traffic of Gb1 to
membranes. In addition, both translational read-through drugs
can restore sufficient endogenous RP2 expression and function
to facilitate the trafficking and plasma membrane association
of Gb1 in RP2-null R120X cells.
G418 and PTC124 restore RP2 function in R120X
iPSC-derived RPE cells
The effect of the TRIDs on the RP2-null R120X iPSC-RPE cel-
lular phenotype was investigated. A single 24 h dose of either
G418 (750 mM) or PTC124 (10 mg/ml) was able to restore
tight IFT20 localization at the basal body and to reduce dispersal
of Golgi components, thereby rescuing the RP2-null phenotype
in patient-derived R120X RPE cells to that of wild-type
iPSC-derived RPE cells (Fig. 6A–H). In addition, plasmamem-
brane localization of endogenous Gb1 in R120X RPE cells
was restored following treatment with G418 and PTC124
(Fig. 7A), and co-localization with the plasma membrane
marker wheat-germ agglutinin (WGA) was confirmed by both
Pearson’s and Mander’s coefficients (Fig. 7B and C). Both
TRIDs showed the same efficiency in these functional assays
at the doses tested, indicating that translational read-through
therapy could be clinically beneficial for patients.
DISCUSSION
In this study we used patient cells to investigate the cellular
defects associated with an RP2 R120X mutation that causes
XLRP, and tested a potential therapy. We characterized fibro-
blast cells and iPSC-derived RPE cells and confirmed that they
are RP2-null cells with no functional RP2 protein. The disease
mechanisms resulting from the loss of RP2 are still unclear.
Although it is widely assumed that the rod photoreceptors are
the siteofprimarypathology, theeffect ofRP2 lossonconephoto-
receptor and RPE function cannot be disregarded, especially
given the prevalence of macular atrophy and choroideremia-like
symptoms associated with loss of RP2 function (11). Several
retinal degenerative diseases are caused by malfunction of the
photoreceptors, RPE or both. For example, choroideremia is an
X-linked retinal dystrophy, which is characterized by progressive
degeneration of the choriocapillaris, retinal pigment epithelium
Figure 3. Endogenous full-length RP2 cDNA and protein can be restored in R120X fibroblasts by treatment with G418 and PTC124. (A) Treatment of R120X fibro-
blastswith a single 24 h dose of 500 mMG418 significantly increasedRP2mRNA levels comparedwith untreated cells. ∗P ≤ 0.05, values aremean+2 SEM,N ¼ 3.
(B) Agarose gel showing products of RT-qPCR amplification. GAPDHwas used as an amplification control. (C) Treatment of R120X fibroblasts with a single 24 h
doseof750 mM,500 mMG418or10 mg/mlPTC124significantly increasedRP2protein levels comparedwithuntreatedR120Xcells. ∗P ≤ 0.05,values aremean+2
SEM, N ¼ 2. (D) Western blot showing increased RP2 protein levels in G418 and PTC124 treated R120X fibroblasts compared with untreated R120X cells.
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Figure4.Cellular effects ofG418orPTC124onR120Xfibroblast cells. (A)R120Xfibroblastswere treatedwith a single24hdoseof either 750 mMG418or10 mg/ml
PTC124 and stained for IFT20 (red) and pericentrin (green). Scale bar 10 mm. IFT20 is dispersed in untreated R120X fibroblasts compared with control cells. This
phenotype was reversed by treatment with G418 or PTC124. (B) Quantitation of the area of IFT20 staining showing significant improvement of IFT20 dispersal fol-
lowing treatment with either drug. ∗P ≤ 0.05, values are mean+2 SEM, N ¼ 3 independent experiments with 150 cells per experiment. (C, E andG) Control and
R120Xfibroblastswere stainedwith antibodies for the cis (C;GM130), cis-medial (E;Giantin) and transGolgi (G; TGN) components (red) to determine disruption to
any part of the Golgi. Scale bar 10 mm. (D,F andH) Quantitation of Golgi area staining showing that in untreated R120X cells the area of all three Golgi components
per cell is significantly increased comparedwith control fibroblasts, indicating lack of Golgi cohesion in these RP2-null cells. Treatment with either G418 or PTC124
restored the R120X Golgi area to control levels. ∗P ≤ 0.05, values are mean+2 SEM, N ¼ 3 independent experiments with 150 cells per experiment.
978 Human Molecular Genetics, 2015, Vol. 24, No. 4
 at U
CL Library Services on M
arch 6, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
and photoreceptors (15). Recently, a mouse knock-out model for
RP2wasdevelopedand reported tohaveconecelldysfunctionand
degeneration with cone opsin mislocalization (53); however, the
progression of disease in this model appears to be slower than
that observed in XLRP patients. Therefore, detailed investiga-
tion of patient cells could reveal the basis for this difference
and enable us to study distinct retinal cell types in isolation.
Similar to siRNAmediatedRP2knock-down inARPE19cells
(16), both the patient R120X fibroblasts and iPSC-derived RPE
cells had a less compact Golgi and IFT20 was dispersed from
around the basal body. These phenotypes could be rescued by
overexpression of RP2, indicating that they are a consequence
of the loss of RP2 protein. In ciliated cells, RP2 localizes to the
periciliary ridge, the basal body and the Golgi complex
(16,17,20). These structures function in association with each
other to control protein traffic inciliatedcells (54,55),which sug-
gests a role forRP2 in pericentriolar vesicle trafficking and intra-
flagellar transport (IFT). Themolecular basis for the alteration in
Golgi morphology, however, is not currently understood. RP2 is
aGAP forArl3, and expression of a constitutively active form of
Arl3 (Arl3-Q71L) also results in disruption of Golgi cohesion
and dispersal of IFT20 from the basal body (16). Therefore, it
is likely that dysregulation of theGTPase activity of Arl3 under-
lies these changes in Golgi morphology and IFT20 localization.
The incidence and length of cilia were not affected by the loss
of RP2. Therefore, RP2 might be specifically involved in the
traffic of a subset of cilia-associated proteins. These candidate
proteins include; the visual G protein transducin beta subunit,
Gb1, (52), PC2 (17) andNPHP3 (20). PC2 andNPHP3 localiza-
tion was unaffected by the loss of RP2. In contrast, RP2-null
Figure 5.G418 and PTC124 restore sufficient RP2 function to facilitate plasmamembrane association of Gb1. (A) Immunofluorescence showing FLAG-Gb1 asso-
ciationwith the plasmamembranewhen expressed in control fibroblasts, or when co-expressedwith RP2 or HA-Gg1 in R120Xfibroblasts. FLAG-Gb1was detected
with FLAG antibody (red) and the plasmamembrane is highlightedwith anti-cadherin (green). Treatmentwith a single 24 h dose of either 750 mMG418 or 10 mg/ml
PTC124 restored FLAG-Gb1 plasma membrane localization in the absence of RP2 or HA-Gg1. The inset shows a higher magnification of the region boxed in the
merge image. Scale bar 10 mm. (B andC) Quantitation ofGb1 plasmamembrane association calculated using Pearson’s (B) andMander’s (C) co-localization coeffi-
cients for FLAG and pan-cadherin, using the JaCOP plug-in and ImageJ software. ∗P ≤ 0.05, values are means+2 SEM, N ¼ 3 biological replicates.
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Figure 6.Suppression of IFT20 andGolgi defectswithTRIDs inR120XRPEcells. (A) R120X iPSC-RPEwere treatedwith a single 24 h dose of either 750 mMG418
or10 mg/mlPTC124andstained for IFT20 (red) andpericentrin (green).Scalebar10 mm. (B) IFT20areawasquantifiedusing ImageJ. IFT20 is significantly dispersed
in untreated R120XRPE comparedwith control RPE cells. This RP2-null cellular phenotype is reversed by treatmentwith either G418 or PTC124. ∗P ≤ 0.05, values
aremeans+2 SEM,N ¼ 3 independent experimentswith 300 cells per experiment. (C,E andG) Control andR120XRPEcellswere stained (red)with antibodies for
the cis, cis-medial and trans Golgi components (C; GM130, E; Giantin and G; TGN) and pericentrin (green) to assess disruption of any part of the Golgi. Scale bar
10 mm. (D, F andH) Golgi area was quantified using ImageJ. In untreated R120XRPE cells the area of all three Golgi components per cell is significantly increased
compared with control RPE cells, indicating lack of Golgi cohesion in these cells. Treatment with G418 or PTC124 restored Golgi cohesion to levels comparable to
control RPE cells. ∗P ≤ 0.05, values are means+2 SEM, N ¼ 3 independent experiments with 300 cells per experiment.
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patient cells had problems efficiently trafficking Gb1 to the
plasma membrane. RP2 can bind Gb1 and Gb1 is released
from RP2 by Arl3-Q71L. Arl3 and its effectors Unc119 and
PDE6d are involved in the membrane traffic of lipidated pro-
teins, including the alpha (acyl) and gamma (prenyl) subunits
of transducin (56,57). Taken together with previous studies on
G protein trafficking, we proposed a model for trafficking of
membrane-associated proteins in photoreceptors in which RP2
acts with Arl3, Unc119 and PDE6d, to target the assembly and
traffic ofmembrane-associated cargo proteins, such as heterotri-
meric transducin, to specificmembranes and co-ordinate protein
traffic (58,59). No differences in G protein traffic were observed
in the retina of RP2 knock-out mice (53), so it remains unclear if
this discrepancy with the human cells reflects a difference in
function between human and mouse RP2, or if it is related to
the levels of G protein subunits in the experimental systems, as
overexpression of Gg1 can efficiently replace RP2 to facilitate
Gb1 membrane association. Here we show that endogenous
Gb1 trafficking to the plasmamembrane of RPE cells is depend-
ent on functional RP2 in human retinal cellular context.
A major advantage of patient-derived cells is that they enable
testing of sequence, or mutation-type, dependent-specific ther-
apies, such as read-through therapies, that could not be tested
on knock-out animal models. Therefore, we analyzed the
effects of RP2 loss and treatment with TRIDs (G418 and
PTC124) on patient-derived fibroblasts and iPSC-derived RPE
cells, which displayed the same morphological characteristics
as typical RPE cells.
G418 is an aminoglycoside that is proposed to suppress NMD
by inhibiting translationally active ribosomes and thereby lower-
ing the efficiency of the cellular proof-reading machinery (60).
G418 has successfully suppressed PTCs in cellular models
(61), as well as in patients with Duchenne muscular dystrophy
and cystic fibrosis (62–66). However, the clinical disadvantages
ofG418 treatment are thehigh level of toxicity for long-termuse,
such as nephron- and ototoxicity, as well as the requirement for
intramuscular or intravenous drug delivery (67). In contrast,
PTC124 has an excellent preliminary safety and tolerability
profile and can be taken orally (47,68). PTC124 has been suc-
cessfully used in treatment of arylsulfatase B (ARSB associated
mucopolysaccharidosis) (69) andPTC124 is currently in clinical
trials for the treatment of cystic fibrosis (70) and Duchenne
muscular dystrophy (46); however, the clinical findings of
these studies are not conclusive. In a Phase 3 clinical trial of
PTC124 treatment for cystic fibrosis, patients did not have an
increased lung function following treatment (70). In contrast,
the majority of patients in a Phase 2a clinical trial for Duchenne
muscular dystrophy showed aPTC124mediated increase in dys-
trophin levels (46). The mechanism of action for PTC124 is still
controversial. It has been suggested that the activity of PTC124
Figure 7.TRID treatment can enhance endogenousGb1 traffic inR120X iPSC-RPE. (A) Control andR120XRPEcellswere stained for endogenousGb1 (green) and
themembranemarkerWGA(red).Gb1 plasmamembrane localization is disrupted inR120XRPEcells, but restoredwith treatment of eitherG418or PTC124. (B and
C) Gb1 plasma membrane staining was quantified by calculating the Pearson’s (B) andMander’s (C) co-localization coefficient in cells co-stained for Gb1 and the
plasmamembranemarkerWGA, using the JaCOPplug-in and ImageJ software. ∗P ≤ 0.05, values aremean+2 SEM,N ¼ 3 independent experimentswith 300 cells
per experiment.
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in luciferase-based in vitro experiments is due to PTC124′s post-
translational stabilization of the luciferase reporter and not a
genuine read-through effect (71). However, PTC124 treatment
restored 20–25%ofdystrophinprotein levels in themdx-mouse,
a model for Duchenne muscular dystrophy, in vitro and in vivo
(47). In addition, a recent study using a GFP reporter plasmid
showed that PCT124 was effective in inducing full-length
protein expression of GFP containing a stop codon. Computa-
tional modelling of the supramolecular interaction of PTC124
and an mRNA fragment containing a stop codon confirmed
that PTC124 interacts specifically with the stop codon (72).
These findings and our data suggest that PTC124 is indeed
able to promote translational read-through of premature stop
codons.
There is great potential for the topical application of TRIDs to
the eye. In amodel of humanUsher syndrome type 1C (USH1C)
treatment with PTC124 was able to rescue translational read-
through of a patient mutation in the USH1C gene and restored
the functional properties of the protein (48,73). Furthermore,
in a recent study of a mouse model with aniridia (pax6 mouse)
topical administration of PTC124 inhibited disease progression
and even reversed ocular malformations (49).
Treatment of R120X fibroblasts with the established TRID,
G418, caused an increase in RP2 mRNA (40%) and protein
levels (20%) while treatment with PTC124 increased RP2
protein levels (13%), but did not significantly increase RP2
mRNA levels. One possible explanation for this could be a dif-
ference in drug potency or mechanism of action. It is possible
that G418 increases the rate of translational read-through or sta-
bilizes RP2 mRNA transcripts more efficiently than PTC124,
reflecting the slightly higher amount of RP2 protein. Also
PTC124 and G418 potentially act via different mechanisms in
preventing NMD, for example, by inducing cleavage and inacti-
vation of eukaryotic initiation factors or blocking ribosomal sub-
units involved in transcription. Interestingly, PTC124 is able to
promote read-through of all three nonsense codons, with the
highest read-through of stop codon UGA, which is the R120X
stop codon, followed by UAG and then UAA (47).
In this study, we restored13–20%ofRP2 protein inR120X
patient cells, similar to the level of restored dystrophin protein
achieved by PTC124 treatment in the mdx mouse (47). Of
the 13–20% of restored RP2 protein, only a fraction is likely
to be the same sequence as wild-type protein, while the rest of
the full-length RP2 could harbour different amino acids at pos-
ition 120, since the suppression of stop codons occurs through
the random mispairing of a near cognate tRNA with the stop
codon. Therefore, probably much less than 13–20% of full-
length, wild-type sequence RP2 protein were restored, but
importantly our data show that only low levels of full-length
functional RP2 are required to rescue the observed phenotypes.
Furthermore, we were able to demonstrate that the TRIDs
restored full-length protein, was functional. This was possible
through advances in understanding the function of RP2, which
showed that loss of RP2 in cells causes IFT20 and Golgi disper-
sal, as well as mislocalization of Gb1 (16,52). These findings
provide a vital tool to assess the efficacy of TRIDs to restore
functional RP2 protein and therefore reversal of the observed
disease phenotypes. The development of iPSC patient cell
lineswill enable the investigation of other cellular consequences
of RP2 loss, and in defining the molecular basis for disease.
Further investigation of the RPE biology will determine if
these cells are fully functional, for example, in photoreceptor
phagocytosis, visual cycle function and ion homeostasis. It
might also be possible to differentiate these iPS cells into photo-
receptors and investigate their biology. Photoreceptors are
highly specialized ciliated cells and their cilia are complex orga-
nelles, which require efficient protein trafficking. It is possible
that RP2 is required to fulfil these specialized needs, and it will
be important to test whether these TRIDs have a significant
effect in vivo with further detailed investigation.
In conclusion, this proof-of-concept study has demonstrated
that small molecules, such as PTC124, and aminoglycosides,
such as G418, can promote read-through of PTC in RP2 and
can therefore potentially restore gene function in patients.
This, together with the ability to differentiate RPE cells from
patient-derived iPS cells provides a compelling case to evaluate
the potential therapeutic value of this approach.
MATERIALS ANDMETHODS
Study subjects
After informed consent a skin biopsy was obtained from a male
RP2 patient with a diagnostically confirmed R120X mutation,
and from healthy control male individuals. The study followed
the tenets of the Declaration of Helsinki and was approved by
the Moorfields and Whittington Hospitals’ local Research
Ethics Committees and theNRESCommittee LondonRiverside
Ethics Committee (REC 12/LO/0489).
Reagents
G418 was obtained from Sigma-Aldrich and cells were treated
with a single 24 h dose. PTC124 (Ataluren) was obtained from
Selleckchem (Boston, USA). Cells were treated with a single
24 h dose before analysis. LabTAQ High Green Rox (Labtech,
Uckfield, UK) was used for qPCR amplifications.
Cell culture of fibroblasts from skin biopsies
Five millimeter punch biopsies were obtained from an RP2
patient and a healthy male control under local anaesthetic. The
biopsies were sectioned into smaller (1 mm) pieces using
sterile scalpel blades and placed into a 6-well plate. The tissue
was exposed to a minimal amount of fibroblast growth media
(DMEM, 10% foetal calf serum, 1 mM non-essential amino
acids, 1 mM GlutamaxTM and penicillin–streptomycin, Life
Technologies, Germany), overlaid with a sterile coverslip over-
night and incubated at 378Cin5%CO2 in ahumidified incubator.
The following day 2 ml of fresh medium was added. The tissue
was cultured until sufficient fibroblast outgrowth had occurred
(4 weeks) for further passage of cells. Fibroblast cells were
washed in PBS, dissociated using TrypLETM Express (Life
Technologies, Germany) and re-plated at a split ratio of 1:3.
For maintenance, the media was replaced every 3–4 days and
cells passaged when 80–90% confluent. gDNA was extracted
from fibroblast cells using the GeneEuteTM Mammalian
Genomic DNAminiprep Kit (Sigma) and used in direct sequen-
cing to confirm the RP2 mutation. For immunofluorescence
staining, cells were cultured in 8-well chamber slides (VWR,
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Lutterworth, UK). Cells for western blotting were plated into
6-well plates (Nunc, Fisher Scientific, UK). For rescue and
Gb1 trafficking experiments, fibroblasts were transfected by
electroporation with 2 mg of Gb1-FLAG and 2 mg of either
GFP alone, RP2-GFP or Gg1-HA.
Reprogramming patient-derived skin cells to IPSCs
iPSCswere generated fromfibroblast cells in growthphase using
integration-free episomal vectors obtained from Addgene:
pCXLE-hOCT3/4-shp53-F (Addgene plasmid 27077), pCXLE-
hSK (Addgene plasmid 27078) and pCXLE-hUL (Addgene
Plasmid 27080) (74). Fibroblast cells were dissociated in
TrypLETM Express, resuspended in PBS and counted using a
haemocytometer. Of note,1× 106 cells were isolated, resus-
pended in 100 ml Nucleofectorw solution from the Cell Line
NucleofectorwKit R (Lonza) andmixed with 1 mg of each episo-
mal plasmid. Samples were transferred into a cuvette and electro-
porated using an Amaxa Nucleofector I device. Following
electroporation cells were plated onto a 0.2% gelatin-coated
10 cm2 dish, cultured in fibroblast growth medium containing
0.5 mM sodium butyrate at 378Cwithin a 5% CO2 humidified in-
cubator. Themediumwas changed daily. OnDay 7 the cells were
dissociatedusingTrypLETMExpressandplatedonto6-well plates
coated with Corningw Matrigelw basement membrane matrix
(Corning) at a density of 2 × 105 cells per well and maintained
overnight in fibroblast growth medium. The following day the
media was changed to mTeSR1 (Stem Cell Technologies),
which was replaced daily until iPSC colonies appeared (approxi-
mately at Day 30). Clonal iPSC colonies were identified by
morphology and StainAlive DyLightTM TRA-1-81 staining
(Stemgent) and isolated using mechanical dissection. iPSC lines
weremaintained initially inmTeSR1usingmechanical dissection
for the first four passages, after which dispase enzymatic passa-
ging was performed.
Differentiation of iPSCs to RPE
iPSCweredifferentiated intoRPEcells by spontaneous differen-
tiation using an established protocol (28,30). RPE cells were
purified by manual isolation of pigmented colonies using cres-
cent blades (Fine Science Tools). Colonies were dissociated by
incubation in Accutase solution (Sigma-Aldrich) for 2–3 h
and plated at a density of 50 000 cells/cm2 in X-Vivo 10 onto
Matrigel-coated tissue culture plastic dishes. The media was
replaced twice weekly for 6–8 weeks, until cells had devel-
oped a confluent pigmented monolayer.
RT-qPCR
To determine the level of RP2 transcript and the efficiency of the
TRIDs treatment, total RNA was extracted from control and
R120X (TRID treated and untreated) fibroblasts using RNeasy
extraction kit (Qiagen, Crawley, UK) according to the manufac-
turer’s instructions. cDNA was reverse transcribed using a
cDNA synthesis kit (Bioline, London, UK) with a random
hexamer primer mix. For quantitative real-time PCR amplifica-
tions RP2 was amplified rom exon 1 to exon 2 using the follow-
ing, intron spanning primers: 5′-AAGCAGTACAGCTGGGAT
CA-3′ and 5′-TCTTGAATGAGAAACTGTTGTCC-3′. GAPDH
andb-tubulinwere used as amplification controls and to normal-
ize RP2 expression using the following forward and reverse
primers: GAPDH 5′-CCCCACCACACTGAATCTCC-3′ and
5′-GGTACTTTATTGATGGTACATGACAAG-3′; b-tubulin
5′-AATCCCCACCTTTTCTTACTCC-3′ and 5′-AAAGATGG
AGGAGGGTTCCC-3′.QuantitativePCRreactionswere runon
a StepOne Plus Real Time PCRSystem (Life Technologies) and
analyzed using the Comparative CT experiment option in the
StepOne software (Version 2.3). For the analysis of iPSC gene
expression in clonal lines RNAwas extracted from undifferenti-
ated iPSC cultures and converted into cDNA using the Super-
Script Reverse Transcriptase III Kit (Life Technologies) using
oligo-dT priming according to the manufacturer’s instructions.
Primers specific to the episomal reprogramming vector or en-
dogenous coding sequence of Oct4, Klf4, Sox2, Lin28 and
c-myc (74) and control genes (GAPDH, b-tubulin and B2M;
(28) were used to amplify iPSC cDNA in the StepOne Plus
Real Time PCR System using Power SYBRw Green Master
Mix (Life Technologies, Germany) according to the manufac-
turer’s instructions. Pluripotency gene expression was normal-
ized to the multiple control genes and endogenous expression
plotted as the target expression relative to the episomal vector.
Antibodies
Production and characterization of affinity-purified sheep poly-
clonal RP2 antisera S974 has been described previously (12,51).
Mouse anti-M2 FLAG (1:1000, Sigma-Aldrich) was used to
detect FLAG-Gb1. The guinea-pig anti-IFT20 (1:200) antibody
was a gift from Dr J. C. Besharse (Cell Biology Department,
Medical College of Wisconsin, Milwaukee, USA). The follow-
ing antibodies were used as Golgi markers: GM130 (1:100,
Clone 35, BD Biosciences, Oxford, UK), TGN-46 (1:1000,
Abcam), Giantin (1:500, Abcam). Rabbit pan-cadherin (1:500,
Abcam) was used to stain membrane structures. Rabbit anti-
pericentrin (1:2000, Abcam) and mouse anti-pericentrin (1:1000,
Abcam) were used as centrosomal/basal body markers. The
mouse anti-fibroblast surface protein antibody (1:100) was pur-
chased from Sigma. The rabbit anti-Arl13b antibody (1:500,
Protein TechGroup) and mouse-anti acetylated alpha tubulin
(1:1000, Sigma-Aldrich) were used as cilia markers. Goat
anti-Polycystin-2 (1:50) and rabbit anti-Gb1 antibody (1:200)
were purchased from Santa Cruz and rabbit anti-NPHP3
(1:100) was from Proteintech. Pluripotency markers for iPSC
staining were: rabbit anti-Oct4 (1:1000, Abcam) rabbit anti-
Nanog (1:1000, Abcam), mouse anti-Tra-1-60 (1:1000, Life
Technologies), mouse anti-Tra-1-81 (1:1000, Life Technolo-
gies). Markers for staining of RPE cells were: mouse anti-mitf
(1:300, Neomarkers, Fremont, CA), mouse anti-Pmel17 (1:1000,
DAKO), rabbit anti-ZO1 (1:500, Invitrogen), mouse anti-
Bestrophin (1:1000, Abcam), rabbit anti-MerTK (1:50, Abcam),
mouse anti-ATP1B1 (1:100, Abcam), mouse anti-RPE65
(MAB5428, 1:500, Merck Millipore, Watford, UK).
Western blotting
For western blotting of RP2 or GAPDH protein expression,
crude sheep anti-RP2 antibody (1:2000) or mouse anti-GAPDH
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antibody (1:40 000, Sigma-Aldrich) were used respectively.
Secondary antibodies used were horseradish peroxidase (HRP)
conjugated goat anti-sheep, donkey anti-rabbit or goat anti-
mouse antibodies (Stratech). Blots were developed using the
enhanced chemiluminescence (ECL) western blotting detection
system (GE Healthcare). Protein levels were quantified using
ImageJ software.
Immunocytochemistry (ICC)
For ICC, cells were washed twice in PBS and either fixed in
100% ice-cold methanol for 2 min or 4% paraformaldehyde
(PFA) for 10 min. For sectioning, RPE cells were washed in
PBS and fixed in the cell culture well in 4% PFA for 30 min at
48C. The RPE monolayer was carefully lifted off with a cell
scraper and washed gently in 30% sucrose. Fresh 30% sucrose
was added and RPE cells stored at 48C over night. The RPE
monolayer was embedded in O.C.T. compound (VWR), frozen
in a dry ice/acetone slurry stored at2808C prior to cryosection-
ing at 10 mm onto Superfrost plus slides (VWR). RPE sections
and other cells were permeabilized with 0.2% Triton X-100 in
PBS for 10 min and subsequently incubated for 1 h in blocking
buffer [3% bovine serum albumin (BSA), 10% normal donkey
serum in PBS] to avoid non-specific antibody binding. Follow-
ing block, cells were incubated for 1 h with primary antibodies
at the appropriate titre. After washing with PBS cells were
then incubated with fluorescent-labelled (Cyanine2 or
Cyanine3) secondary antibodies (1:100, Stratech, Newmarket,
Suffolk, UK) for 1 h in 3% BSA in PBS. Following several
washes with PBS, cells were incubated for 5 min with 2 mg/ml
4′,6-diamidino-2- phenylindole (DAPI, Sigma-Aldrich) in
PBS to stain the nuclei. Confocal images were obtained using
the LSM700 microscope (Carl Zeiss MicroImaging) and ana-
lyzedusing theLSMImageBrowser software (Carl ZeissMicro-
Imaging), prior to export and image processing and annotation
using Adobe Photoshop and Illustrator. Co-localization of pro-
teins at the plasmamembranewas determined bymorphological
assessment of fluorescently labelled cells using a Nikon Eclipse
80i microscope and Nikon NIS-Elements software (Basic Re-
search, Version 2.2, Nikon). The Pearson’s correlation coeffi-
cient and the Mander’s co-localization coefficient were
determined to corroborate the morphological assessment and
quantify co-localization, as previously described (75). Briefly,
per treatment a minimum of three biological replicates were
analyzed using the ImageJ JACob plugin software. The area of
IFT20 and Golgi staining was analyzed for each organelle
using a confocal projection and the Threshold plugin in ImageJ.
Statistical analysis
Statistical analyses were performed using the excel software.
Quantitative PCR reactions were analyzed using the Compara-
tive CT experiment option in the StepOne software (Version
2.3). Significance was determined by Student’s t test and
co-localization correlations were determined using Pearson’s
and Mander’s correlations in ImageJ with the JACoP plug-in.
Data are presented as means+ 2 SEM. Significance levels
were set when P, 0.05 (∗), P, 0.01 (∗∗), P, 0.001 (∗∗∗).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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